- Home
- CGEN vs ANTX Comparison
CGEN vs ANTX Comparison
Compare CGEN & ANTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CGEN | ANTX |
|---|---|---|
| Founded | 1993 | 2017 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 201.8M | 172.9M |
| IPO Year | 2001 | 2022 |
Fundamental Metrics
Financial Performance| Metric | CGEN | ANTX |
|---|---|---|
| Price | $2.13 | $4.01 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 2 |
| Target Price | $4.60 | ★ $9.00 |
| AVG Volume (30 Days) | 232.1K | ★ 264.0K |
| Earning Date | 11-09-2026 | 11-20-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 32.56 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.43 | $1.00 |
| 52 Week High | $3.24 | $7.19 |
Technical Indicators
Market Signals| Indicator | CGEN | ANTX |
|---|---|---|
| Relative Strength Index (RSI) | 52.96 | 44.29 |
| Support Level | $1.98 | $3.91 |
| Resistance Level | $2.20 | $5.11 |
| Average True Range (ATR) | 0.10 | 0.33 |
| MACD | 0.02 | 0.06 |
| Stochastic Oscillator | 77.61 | 37.76 |
Price Performance
Historical ComparisonAbout CGEN Compugen Ltd.
Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing Unigen, its AI/ML-powered computational discovery capabilities, to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Its immuno-oncology pipeline consists of four clinical-stage programs: COM701, COM902, rilvegostomig, and GS-0321 (previously COM503), targeting immune checkpoints the company discovered computationally. The company's revenues are generated mainly from collaborative and license agreements. Geographically, it generates maximum revenue from the United Kingdom, and the rest from the United States.
About ANTX AN2 Therapeutics Inc.
AN2 Therapeutics Inc is a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform. The company has a pipeline of boron-based compounds in development for Chagas disease, non-tuberculous mycobacterial (NTM) and melioidosis, along with early-stage programs focused on targets in infectious diseases and oncology. Product candidate AN2-502998 Epetraborole.